Cubist Inks Deal To Buy Trius, Optimer For Up To $1.6B
Cubist Pharmaceuticals Inc. said Tuesday it would acquire all shares of Trius Therapeutics Inc. and Optimer Pharmaceuticals Inc. in two transactions worth up to $1.62 billion, boosting the company's leadership in...To view the full article, register now.
Already a subscriber? Click here to view full article